Nakkam N et al. The impact of genetic polymorphisms of drug metabolizing enzymes on the pharmacodynamics of clopidogrel under steady state conditions. Drug Metab Pharmacokinet. 2015;30:295-304. | PK/PD | PK/PD | |
Alzubiedi S et al. Pharmacogenetic-guided warfarin dosing algorithm in African-Americans. J Cardiovasc Pharmacol. 2016;67:86-92. | Review | 2016-01 | |
Leusink M et al. Seventeen years of statin pharmacogenetics: a systematic review. Pharmacogenomics. 2016;17:163-80. | Systematic Review | 2016-01 | |
Sridharan K et al. Association of genetic polymorphisms of CYP2C9 and VKORC1 with bleeding following warfarin: a case-control study. Curr Clin Pharmacol. 2016;11:62-8. | Case Control | 2016-01 | |
Peterson JF et al. Physician response to implementation of genotype-tailored antiplatelet therapy. Clin Pharmacol Ther. 2015 Dec 22 [Epub ahead of print]. | Retrospective Analysis | 2015-12 | |
Shi C et al. Pharmacogenetics-based versus conventional dosing of warfarin: a meta-analysis of randomized controlled trials. PLoS One. 2015;10:e0144511. | Meta-Analysis | 2015-12 | |
Trompet S et al. Non-response to (statin) therapy: the importance of distinguishing non-responders from non-adherers in pharmacogenetic studies. Eur J Clin Pharmacol. 2015 Dec 19 [Epub ahead of print]. | Retrospective Analysis | 2015-12 | |
Mitchell D et al. Economic evaluation of a pharmacogenomic test for statin-induced myopathy in cardiovascular high-risk patients initiating a statin. Value Health. 2015;18:A396. | Cost-Effectiveness Analysis | 2015-11 | |
Nishimura AA et al. Physician perspectives of CYP2C19 and clopidogrel drug-gene interaction active clinical decision support alerts. Int J Med Inform. 2016;86:117-25. | Survey | 2015-11 | |
Gor D et al. Cost-effectiveness of a novel pharmacist guided warfarin pharmacogenetic service. Value Health. 2015;18:A390. | Cost-Effectiveness
Analysis | 2015-11 | |
Malhotra N et al. A pharmacodynamic comparison of a personalized strategy for anti-platelet therapy versus ticagrelor in achieving a therapeutic window. Int J Cardiol. 2015;197:31825. | Retrospective Cohort | 2015-10 | |
Li Y et al. VKORC1 -1639G/A and 1173 C/T genetic polymorphisms influence individual differences in warfarin maintenance dose. Genet Test Mol Biomarkers. 2015;19:48893. | Cohort | 2015-09 | |
Han Y et al. Influence of genetic polymorphisms on clopidogrel response and clinical outcomes in patients with acute ischemic stroke CYP2C19 genotype on clopidogrel response. CNS Neurosci Ther. 2015;21:6927. | Case-Control | 2015-09 | |
Saab YB et al. Optimizing clopidogrel dose response: a new clinical algorithm comprising CYP2C19 pharmacogenetics and drug interactions. Ther Clin Risk Manag. 2015;11:1421-7. | PK/PD | 2015-09 | |
Zhang J et al. The influence of VKORC1 gene polymorphism on warfarin maintenance dosage in pediatric patients: A systematic review and meta-analysis. Thromb Res. 2015;136:955-61 | Meta-Analysis | 2015-09 | |
Jiang M et al. CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis. Pharmacogenet Genomics. 2015;25:609-17.
| Cohort | 2015-09 | |
Lin M et al. Association between CYP2C19 Polymorphisms and Outcomes in Cerebral Endovascular Therapy. Am J Neuroradiol. 2016;37:108-13 | Prospective Cohort | 2015-09 | |
Xu H et al. Comparison of the performance of the warfarin pharmacogenetics algorithms in patients with surgery of heart valve replacement and heart valvuloplasty. Thromb Res. 2015;136:5529. | Retrospective Cohort | 2015-09 | |
Collet JP et al. Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study. Eur J Clin Pharmacol. 2015;71:1315-24. | Randomized Controlled Trial | 2015-08 | |
Tabib A et al. Enzyme polymorphism in warfarin dose management after pediatric cardiac surgery. Res Cardiovasc Med. 2015;4:e27963. | Prospective Cohort | 2015-08 | |
Shaw K et al. Clinical practice recommendations on genetic testing of CYP2C9 and VKORC1 variants in warfarin therapy. Ther Drug Monit. 2015;37(4):42836. | Systematic Literature Review | 2015-08 | |
Knauer MJ et al. Clopidogrel and CYP2C19: pharmacogenetic testing ready for clinical prime time? Clin Chem. 2015;61:1235-40. | Opinion | 2015-08 | |
Abohelaika S et al. Influence of CYP2C9 polymorphism on fall in International Normalized Ratio in patients interrupting warfarin therapy before elective surgery. J Thromb Haemost. 2015;13:1436-40. | Prospective Cohort | 2015-08 | |
Wypasek E et al. CYP2C9 polymorphism and unstable anticoagulation with warfarin in patients within the first 3 months following heart valve replacement. Adv Clin Exp Med. 2015;24:607-14. | Case-Control | 2015-08 | |
Pan Y et al. PGWD: Integrating Personal Genome for Warfarin Dosing. Interdiscip Sci. 2016;8:23-7. | Description of Web Tool | 2015-08 | |
Dai DP et al. Identification and characterization of a novel CYP2C9 allelic variant in a warfarin-sensitive patient. Pharmacogenomics. 2015;16:1475-86 | Description of Novel Variant | 2015-08 | |
Wei Y-Q et al. Cytochrome P450 CYP 2C19*2 associated with adverse 1-year cardiovascular events in patients with acute coronary syndrome. PLoS ONE. 2015;10(7):e0132561. | Prospective Cohort | 2015-07 | |
You JH. Universal versus genotype-guided use of direct oral anticoagulants in atrial fibrillation patients: a decision analysis. Pharmacogenomics. 2015;16:1089-100 | Retrospective Cohort | 2015-07 | |
Tang T et al. Genotype-Guided Dosing of Coumarin Anticoagulants: A Meta-analysis of Randomized Controlled Trials. J Cardiovasc Pharmacol Ther. 2015;20:38794. | Meta-Analysis | 2015-07 | |
Belley-Cote EP et al. Genotype-guided versus standard vitamin K antagonist dosing algorithms in patients initiating anticoagulation. A systematic review and meta-analysis. Thromb Haemost. 2015 Jul 9 [Epub ahead of print]. | Meta-Analysis | 2015-07 | |
Rehman KU et al. Allele frequency distribution of CYP2C19*2 allelic variants associated with clopidogrel resistance in cardiac patients. Exp Ther Med. 2015;10(1):30915. | Cross-Sectional | 2015-07 | |
Santos PC et al. Development of a pharmacogenetic-based warfarin dosing algorithm and its performance in Brazilian patients: highlighting the importance of population-specific calibration. 2015;16:865-76. | Cross Sectional | 2015-07 | |
Yang Y et al. The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19. Expert Opin Drug Metab Toxicol. 2015 Jul 14 [Epub ahead of print]. | Opinion | 2015-07 | |
Roden DM. Cardiovascular pharmacogenomics: current status and future directions. J Hum Genet. 2015 Jul 16 [Epub ahead of print]. | Review | 2015-07 | |
Limdi NA et al. Race influences warfarin dose changes associated with genetic factors. Blood. 2015;126:539-45.
| Prospective cohort | 2015-07 | |
Limdi NA et al. Race influences warfarin dose changes associated with genetic factors. Blood. 2015;126:539-45. | Prospective Cohort | 2015-07 | |
Price ET. Warfarin pharmacogenomics and African ancestry. Blood. 2015;126:434-6. | Opinion | 2015-07 | |
Johnson SG et al. Financial analysis of CYP2C19 genotyping in patients receiving dual antiplatelet therapy following acute coronary syndrome and percutaneous coronary intervention. J Managed Care Spec Pharm. 2015;21:5527. | Cost-effectiveness analysis | 2015-07 | |
Bryk A et al. Warfarin metabolites in patients following cardiac valve implantation: a contribution of clinical and genetic factors. Cardiovasc Drugs Ther. 2015;29:257-64. | Prospective Cohort | 2015-06 | |
Sleder AT et al. Cardiovascular pharmacokinetics, pharmacodynamics, and pharmacogenomics for the clinical practitioner. J Cardiovasc Pharmacol Ther. 2015 Jun 8 [Epub ahead of print]. | Perspective | 2015-06 | |
Kobayashi M et al. A randomized study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of clopidogrel in three different CYP2C19 genotype groups of healthy Japanese subjects. J Atheroscler Thromb. 2015 Jun 9 [Epub ahead of print]. | PK/PD | 2015-06 | |
Kaufman AL et al. Evidence for clinical implementation of pharmacogenomics in cardiac drugs. Mayo Clin Proc. 2015;90:71629. | Systematic Review | 2015-06 | |
Hokimoto S et al. Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in coronary heart disease patients during dual antiplatelet therapy. Thromb Res. 2015;135:10816. | Prospective Cohort | 2015-06 | |
Hernandez W et al. Novel single nucleotide polymorphism in CYP2C9 is associated with changes in warfarin clearance and CYP2C9 expression levels in African Americans. Transl Res. 2015;165:6517. | PK / PD | 2015-06 | |
Ross S et al. Use of genetic data to guide therapy in arterial disease. J Thromb Haemost. 2015;13 Suppl 1:S2819. | Review | 2015-06 | |
Kimmel SE. Warfarin pharmacogenomics: current best evidence. J Thromb Haemost. 2015;13 Suppl 1:S26671. | Meta-Analysis | 2015-06 | |
Pereira NL et al. Clinical implementation of cardiovascular pharmacogenomics [Comment]. Mayo Clin Proc. 2015;90:7014. | Comment | 2015-06 | |
Jiménez-Varo E et al. Extrapolation of acenocoumarol pharmacogenetic algorithms. Vascul Pharmacol. 2015 Jun 27 [Epub ahead of print]. | Cohort | 2015-06 | |
upe S et al. Clinical application of genotype-guided dosing of warfarin in patients with acute stroke. Arch Med Res. 2015;46:255-73. | Prospective Cohort | 2015-05 | |
Park YK et al. Lack of association of clinical factors (SAMe-TT2R2) with CYP2C9/VKORC1 genotype and anticoagulation control quality. J Stroke. 2015;17:1928. | Prospective Cohort | 2015-05 | |
Nozari Y et al. The impact of cytochrome P450 2C19 polymorphism on the occurrence of one-year in-stent restenosis in patients who underwent percutaneous coronary intervention: A case-match study. Anatol J Cardiol. 2015;15:34853. | Cross Sectional | 2015-05 | |
Golukhova EZ et al. Clopidogrel response variability: impact of genetic polymorphism and platelet biomarkers for predicting adverse outcomes poststenting. Am J Ther. 2015;22:22230. | Case Series | 2015-05 | |
Darbar D. The role of pharmacogenetics in atrial fibrillation therapeutics - Is personalized therapy in sight? J Cardiovasc Pharmacol. 2015 May 9 [Epub ahead of print]. | Perspective | 2015-05 | |
Cavallari LH et al. Pharmacogenomics in cardiology - genetics and drug response: 10 years of progress. Future Cardiol. 2015;11:2816. | Commentary | 2015-05 | |
McDonough CW et al. CYP2C19 metabolizer status and clopidogrel efficacy in the secondary prevention of small subcortical strokes (SPS3) study. J Am Heart Assoc. 2015;4:e001652. | Cohort | 2015-05 | |
Li JH et al. SLCO1B1 genetic variants, long-term low-density lipoprotein cholesterol levels and clinical events in patients following cardiac catheterization. Pharmacogenomics. 2015;16:44958. | Retrospective Cohort | 2015-04 | |
Yang J et al. CYP2C19 LOF alleles confer no risk for HTPR but higher risk for recurrent ischemic events in clopidogrel treated elderly ACS patients. Int J Cardiol. 2015;189:225–7. | Letter | 2015-04 | |
Li X et al. Clinical benefits of pharmacogenetic algorithm-based warfarin dosing: meta-analysis of randomized controlled trials. Thromb Res. 2015;135(4):6219. | Meta-Analysis | 2015-04 | |
Tang HL et al. Limited clinical utility of genotype-guided warfarin initiation dosing algorithms versus standard therapy: a meta-analysis and trial sequential analysis of 11 randomized controlled trials. Pharmacogenomics J. 2015 Apr 14 [Epub ahead of print]. | Meta-analysis | 2015-04 | |
So DYF et al. A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study. Pharmacogenomics J. 2015 Apr 7 [Epub ahead of print]. | Prospective, randomized | 2015-04 | |
Shahabi P et al. Cardiovascular pharmacogenomics; state of current knowledge and implementation in practice. Int J Cardiol. 2015;184:772795. | Review | 2015-04 | |
Oikonomou E et al. Genetic testing and antiplatelet treatment: Still way to go? Int J Cardiol. 2015;187:63–5. | Editorial | 2015-04 | |
Niu X et al. CYP2C19 polymorphism and clinical outcomes among patients of different races treated with clopidogrel: a systematic review and meta-analysis. J Huazhong Univ Sci Technolog Med Sci. 2015;35:147–56. | Meta-analysis | 2015-04 | |
Hokimoto S et al. Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in choronary heart disease patients during dual antiplatelet therapy. Thromb Res. 2015;135:1081-6. | Prospective Cohort | 2015-04 | |
Samardzic J et al. CYP2C19*2 genotype influence in acute coronary syndrome patients undergoing serial clopidogrel dose tailoring based on platelet function testing: Analysis from randomized controlled trial NCT02096419. Int J Cardiol. 2015;186:282–5. | Post-hoc analysis | 2015-03 | |
Abohelaika S et al. The impact of genetics on the management of patients on warfarin awaiting surgery. Age Ageing. 2015 Mar 10 [Epub ahead of print]. | Case Report | 2015-03 | |
Mega JL et al. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015 Mar 10 [Epub ahead of print]. | Sub-Group Analysis | 2015-03 | |
Marume K et al. Intraprocedural thrombotic event during coronary intervention depends on CYP2C19 genotype and is a predictor of future clinical event. Int J Cardiol. 2015;187:231–33. | Descriptive report | 2015-03 | |
Li S et al. Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus assessed by follow-up optical coherence tomography in Chinese patients receiving clopidogrel. J Thromb Thrombolysis. 2015;40:88-96. | Retrospective cohort | 2015-03 | |
Lee JA et al. Implementation and evaluation of a CYP2C19 genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients. Pharmacogenomics. 2015;16:303–13. | Retrospective Cohort | 2015-03 | |
Barajas MR et al. A patient-centered approach to the development and pilot of a warfarin pharmacogenomics patient education tool for health professionals. Curr Pharm Teach Learn. 2015;7:249–55. | Pilot | 2015-03 | |
Nagai R et al. Factors influencing pharmacokinetics of warfarin in African-Americans: implications for pharmacogenetic dosing algorithms. Pharmacogenomics. 2015;16:217–25. | Lync PK | 2015-03 | |
Li X et al. Clinical benefits of pharmacogenetic algorithm-based warfarin dosing: meta-analysis of randomized controlled trials. Thromb Resh. 2015 Jan 17 [Epub ahead of print]. | Meta-analysis | 2015-01 | |
Tang N et al. The relationship between on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes in Chinese patients. Scand J Clin Lab Invest. 2015a;17. | Prospective cohort | 2015-01 | |
Tang T et al. Genotype-guided dosing of coumarin anticoagulants: a meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol Ther. 2015 Jan 8 [Epub ahead of print]. | Meta-analysis | 2015-01 | |
Baranova EV et al. Genotype-guided coumarin dosing: where are we now and where do we need to go next? Expert Opin Drug Metab Toxicol. 2015;114. | Review | 2015-01 | |
Verhoef TI et al. Economic evaluation of a pharmacogenetic dosing algorithm for coumarin anticoagulants in the Netherlands. Pharmacogenomics. 2015;16:101114. | Cost-effective analysis | 2015-01 | |
Birmingham BK et al. Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States. Eur J Clin Pharmacol. 2015 Jan 30 [Epub ahead of print]. | PK | 2015-01 | |
Mitropoulou C et al. Economic evaluation of pharmacogenomic-guided warfarin treatment for elderly Croatian atrial fibrillation patients with ischemic stroke. Pharmacogenomics. 2015;16:13748. | Cost-effective analysis | 2015-01 | |
Carnes CA. What is the role of pharmacogenetics in optimization of warfarin dosing? Trends Cardiovasc Med. 2015;25:423. | Editorial Commentary | 2015-01 | |
Johnson JA et al. Warfarin pharmacogenetics. Trends Cardiovasc Med. 2015;25:3341. | Review | 2015-01 | |
Bousoula E et al. Pharmacogenetics and statin treatment: reality or theory? Curr Vasc Pharmacol. 2015 Jan 30 [Epub ahead of print]. | Review | 2015-01 | |
Chong HY et al. Cost-effectiveness analysis of pharmacogenetic-guided warfarin dosing in Thailand. Thromb Res. 2014;134:127884. | Cost-effectiveness analysis | 2014-12 | |
Drozda K et al. Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans. Pharmacogenet Genomics. 2014 Dec 1 [Epub ahead of print]. | Cohort | 2014-12 | Warfarin: Including genotypes important for African Americans leads to better dose prediction |
Wang X-Q et al. Genetic polymorphisms of CYP2C19*2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome. Gene. 2014a Dec 24 [Epub ahead of print]. | PK | 2014-12 | |
Zhang L et al. Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis. Thromb Res. 2014 Dec 9 [Epub ahead of print]. | Meta-analysis | 2014-12 | |
Wang Z-Q et al. Pharmacogenetics-based warfarin dosing algorithm decreases time to stable anticoagulation and the risk of major haemorrage: an updated meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol. 2014 Dec 30 [Epub ahead of print]. | Meta-analysis | 2014-12 | |
Qiu L-N et al. Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel. Eur J Pharmacol. 2014;747C:2935. | Prospective Cohort | 2014-12 | |
Kawai VK et al. Genotype and risk of major bleeding during warfarin treatment. Pharmacogenomics. 2014;15:197383. | Retrospective Cohort | 2014-12 | |
Hawcutt DB et al. Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects. Pharmacogenomics J. 2014;14:5428. | Cohort | 2014-12 | |
Hopewell JC et al. Pharmacogenomics of statin therapy: any new insights in efficacy or safety? Curr Opin Lipidol. 2014 Dec 25 [Epub ahead of print]. | Review | 2014-12 | |
Xu H et al. Meta-analysis of efficacy and safety of genotype-guided pharmacogenetic dosing of warfarin. Int J Cardiol. 2014;177:6547. | Meta-analysis | 2014-12 | |
Ismail S et al. Genotype- and phenotype-directed antiplatelet therapy selection in patients with acute coronary syndromes. Expert Rev Cardiovasc Ther. 2014;12:12891303. | Review | 2014-11 | |
Konishi A et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism on intra-stent thrombi and lesion outcome after everolimus-eluting stent implantation compared to that after first-generation drug-eluting stent implantation. Int J Cardiol. 2014 Nov 6 [Epub ahead of print]. | Prospective Cohort | 2014-11 | |
Parikh KS et al. Potential applications of pharmacogenomics to heart failure therapies. Heart Fail Clin. 2014;10:599606. | Review | 2014-11 | |
Iwuchukwu OF et al. Genetic variation in the UGT1A locus is associated with simvastatin efficacy in a clinical practice setting. Pharmacogenomics. 2014;15:173947. | Retrospective cohort | 2014-11 | |
Fontana V et al. Large-scale gene-centric analysis identifies polymorphisms for resistant hypertension. J Am Heart Assoc. 2014;3:e001398. |
Cross-sectional | 2014-11 | |
Meyer Zu Schwabedissen HE et al. Function-impairing polymorphisms of the hepatic uptake transporter SLCO1B1 modify the therapeutic efficacy of statins in a population-based cohort. Pharmacogenet Genomics. 2014 Jan 25 [Epub ahead of print]. | Post-hoc analysis | 2014-11 | |
Martínez-Quintana E et al. Clopidogrel: A multifaceted affair. J Clin Pharmacol. 2014; [Epub ahead of print 2014 Oct 18]. | Opinion | 2014-10 | |
Lindgren A. Stroke genetics: a review and update. J Stroke. 2014;16:11423. | Review | 2014-10 | |
Wadelius M. Warfarin pharmacogenetics: it matters if youre black or white. Blood. 2014;124:2171. | Commentary | 2014-10 | |
Guo B et al. Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease. J Vasc Surg. 2014;60:9931001. | Prospective Cohort Study | 2014-10 | |
Postmus I et al. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nat Commun. 2014;5:5068. | Meta-Analysis | 2014-10 | |
Miura G et al. Genetic and non-genetic factors responsible for antiplatelet effects of clopidogrel in Japanese patients undergoing coronary stent implantation: An algorithm to predict on-clopidogrel platelet reactivity. Thromb Res. 2014;134:87783. | Prospective Observational Study | 2014-10 | |
Suarez-Kurtz G et al. Pharmacogenetics of coumarin anticoagulants in Brazilians. Expert Opin Drug Metab Toxicol. 2014 Oct 25 [Epub ahead of print]. | Opinion | 2014-10 | |
De Oliveira Almeida VC et al. Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 Genes and the Therapeutic Warfarin Dose in Brazilian Patients with Thrombosis: A Prospective Cohort Study. Mol Diagn Ther. 2014 Oct 14 [Epub ahead of print]. | Prospective cohort study | 2014-10 | |
Kishan SP et al. Potential Applications of Pharmacogenomics to Heart Failure Therapies, Heart Fail Clin. 2014;10:599606. | Review
| 2014-10 | |
Jiménez-Varo E et al. Prediction of stable acenocoumarol dose by a pharmacogenetic algorithm. Pharmacogenet Genomics. 2014;24:50113. | Retrospective Observational Study | 2014-10 | |
Tresukosol D et al. Effects of Cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease. PLoS ONE. 2014;9:e110188. | Prospective cohort | 2014-10 | |
Oni-Orisan A et al. Pharmacogenomics in heart failure: where are we now and how can we reach clinical application? Cardiol Rev. 2014;22:193-8. | Review | 2014-09 | |
Franchini M et al. Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis. J Thromb Haemost. 2014;12:1480-7. | Meta-Analysis | 2014-09 | New meta-analysis shows 50 percent decrease in serious bleeding with genotype-guided warfarin |
Gurbel PA et al. The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease. 2014;112:589-97. | PK/PD | 2014-09 | |
Sorich MJ et al. CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following PCI and in Asian Populations treated with clopidogrel: a meta-analysis. Circ Cardiovasc Genet. 2014 Sep 25 [Epub ahead of print]. | Meta-Analysis | 2014-09 | |
Hou X et al. Gene polymorphism of cytochrome P450 2C19*2 and clopidogrel resistance reflected by platelet function assays: a meta-analysis. Eur J Clin Pharmacol. 2014;70:1041-7. | Meta-Analysis | 2014-09 | |
Li X et al. Effect of CYP2C9-VKORC1 interaction on warfarin stable dosage and its predictive algorithm. J Clin Pharmacol. 2014 Sep [Epub ahead of print]. | Descriptive | 2014-09 | |
Marbach JA et al. Novel treatments for familial hypercholesterolemia: pharmacogenetics at work. Pharmacotherapy. 2014;34:961-72. | Review | 2014-09 | |
Karnik N et al. CYP2C9FN*3 polymorphism presenting as lethal subdural hematoma with low-dose warfarin. Indian Journal of Pharmacology. 2014;46:549. | Case report | 2014-09 | |
Siller-Matula JM et al. How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors- is an algorithm the answer? Thrombosis and Haemostasis. 2014;112(6). | Systematic review | 2014-09 | |
Jimenes-Varo E et al. Pharmacogenetics role in the safety of acenocoumarol therapy. Thromb Haemost. 2014;112:522-36. | Cohort | 2014-09 | |
Gaikwad T et al. VKORC1 and CYP2C9 genotype distribution in Asian countries. Thromb Res. 2014;134:537-44. | Descriptive | 2014-09 | |
Sun W et al. Variant recurrent risk among stroke patients with different CYP2C19 phenotypes and treated with clopidogrel. Platelets. 2014 Sep 10;15 [Epub ahead of print]. | Prospective cohort | 2014-09 | |
Valentin II et al. Pharmacogenetic association study of warfarin safety endpoints in Puerto Ricans. P R Health Sci J. 2014;33:97-104. | Retrospective cohort | 2014-09 | |
Fontana V et al. An update on the pharmacogenetics of treating hypertension. J Hum Hypertens. 2014 Aug 28 [Epub ahead of print]. | Review | 2014-08 | |
Kirchhof P et al. The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology. Eur Heart J. 2014 Aug; [Epub ahead of print]. | Review
| 2014-08 | New Position Statements Give Guidance on Personalized Medicine In Cardiology, Oncology |
Brunner-Ziegler S et al. Influence of proton pump inhibitors and VKORC1 mutations on CYP2C9-mediated dose requirements of vitamin K antagonist therapy: a pilot study. Br J Haematol. 2014 Aug; [Epub ahead of print]. | Retrospective cohort study
| 2014-08 | |
Arima Y et al. Comparison of the effect of CYP2C19 polymorphism on clinical outcome between acute coronary syndrome and stable angina. J Cardiol. 2014 Aug; [Epub ahead of print]. | Prospective cohort study
| 2014-08 | |
Zhuang W et al. Effect of CYP2C9, CYP4F2 and VKORC1 genetic polymorphisms on pharmacokinetics and pharmacodynamics of mean daily maintenance dose of warfarin in Chinese patients. Blood Coagul Fibrinolysis. 2014 Oct 10 [Epub ahead of print]. | PK/PD Study | 2014-08 | |
Kim HS. The effect of CYP2C19 genotype on the time course of platelet aggregation inhibition after clopidogrel administration. J Clin Pharmacol. 2014;54:8507. | Prospective cohort study
| 2014-08 | |
Horenstein RB et al. Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers. J Clin Pharmacol. 2014;54:86573. | Prospective cohort study
| 2014-08 | Clopidogrel in CYP2C19 Poor Metabolizers: Four-Fold Dose Increase Needed |
Hariharan S et al. Clopidogrel, CYP2C19 and proton pump inhibitors: What we know and what it means. J Clin Pharmacol. 2014;54:884-8. | Commentary | 2014-08 | |
Koller EA et al. Genotype-guided dosing of vitamin K antagonists. N Engl J Med. 2014;370:1761-66. | Correspondence | 2014-08 | |
Langaee T et al. The influence of the CYP2C19*10 allele on clopidogrel activation and CYP2C19*2 genotyping. Pharmacogenet Genomics. 2014;24:381-6. | Genotype analysis | 2014-08 | |
Liu T et al. CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention. Coronary Artery Disease.2014 [Epub ahead of print]. | Prospective cohort | 2014-08 | |
Baranova EV et al. The COAG and EU-PACT Trials: What is the Clinical Benefit of Pharmacogenetic-Guided Coumarin Dosing During
Therapy Initiation? Curr Mol Med. 2014 Aug; [Epub ahead of print]. | Review
| 2014-08 | |
Tang Q et al. Outcomes of pharmacogenetics-guided dosing of warfarin: A systematic review and meta-analysis. Int J Cardiol. 2014;175:58791. | Meta-Analysis
| 2014-08 | |
Stitham J et al. Cardiovascular Pharmacogenetics of Anti-Thrombotic Agents and Non-Steroidal Anti-Inflammatory Drugs. Curr Mol Med.
2014 Aug; [Epub ahead of print]. | Review
| 2014-08 | |
Kazi DS et al. Warfarin, genes, and the (health care) environment. JAMA Intern Med. 2014;174:1338-9. | Commentary | 2014-08 | Meta-analysis of genotype-guided warfarin trials yields disappointing results |
Stergiopoulos K et al. Genotype-guided vs clinical dosing of warfarin and Its analogues: meta-analysis of randomized clinical trials. JAMA Intern Med. 2014;174:1330-8. | Meta-Analysis | 2014-08 | Meta-analysis of genotype-guided warfarin trials yields disappointing results |
Karazniewicz-Lada M, et al. The influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. J Clin Pharmacol. 2014;54:874-80. | Cross-sectional | 2014-08 | |
Munshia A et al. Genetic signatures in the treatment of stroke. Current Pharmaceutical Design. 2014 Aug 26; [Epub ahead of print]. | Review | 2014-08 | |
Horenstein RB et al. Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers. J Clin Pharmacol. 2014;54:865-73. | Crossover study | 2014-08 | Clopidogrel in CYP2C19 poor metabolizers: Four-fold dose increase may be needed |
Franchini M et al. Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis. J Thromb Haemost. 2014; [Epub ahead of print]. | Meta-Analysis | 2014-07 | |
Stimpfle F et al. Impact of point-of-care testing for CYP2C19 on platelet inhibition in patients with acute coronary syndrome and early dual antiplatelet therapy in the emergency setting. Thromb Res. 2014 May 10. [Epub ahead of print]. | Retrospective cohort study | 2014-07 | |
Sardella G et al. The importance of genotype variation beyond different antiplatelet therapy in nonresponder patients. J Am Coll Cardiol. 2014;64:333-4. | Letter | 2014-07 | |
Cavallari LH et al. Warfarin pharmacogenetics: to genotype or not to genotype, that is the question. Clin Pharmacol Ther. 2014;96:22-4. | Commentary | 2014-07 | |
Hawcutt D et al. Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects. Pharmacogenomics J. 2014. [Epub ahead of print]. | Cross-sectional analysis | 2014-07 | |
Depta J et al. Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction. Pharmacogenomics J. 2014; [Epub ahead of print]. | Retrospective analysis | 2014-07 | |
Bergmeijer TO et al. CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients: rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study. Am Heart J. 2014;168:1622. | Descriptive | 2014-07 | |
Mizobe M, et al. Impact of CYP2C19 polymorphism on clinical outcome following coronary stenting is more important in non-diabetic than diabetic patients. Thromb Res. 2014 Apr 26; [Epub ahead of print]. | Prospective cohort study | 2014-07 | |
Gryn SE et al. Pharmacogenomics, lipid disorders, and treatment options. Clin Pharmacol Ther. 2014;96:36-47. | Review | 2014-07 | |
Hata M et al. Incidence of Drug Interaction When Using Proton Pump Inhibitor and Warfarin According to Cytochrome P450 CYP2C19 (CYPCYP2C19) Genotype in Japanese. Thorac Cardiovasc Surg. 2014 Jul; [Epub ahead of print]. | Prospective cohort | 2014-07 | |
Cavallari LH et al. Warfarin pharmacogenetics: to genotype or not to genotype, that is the question. Clin Pharmacol Ther. 2014;96:224. | Review
| 2014-07 | |
Ramsey L et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update. Clin Pharmacol Ther. 2014; [Epub ahead of print].
| Guideline | 2014-07 | Updated SLCO1B1simvastatin guideline provides resources to support clinical implementation |
Hou X et al. Gene polymorphism of cytochrome P450 2C19*2 and clopidogrel resistance reflected by platelet function assays: a meta-analysis. Eur J Clin Pharmacol. 2014;70:1041-7. | Meta-Analysis | 2014-07 | |
Goulding R et al. Genotype-guided Drug Prescribing: A Systematic Review and Meta-analysis of Randomized Control Trials. Br J Clin Pharmacol. 2014; [Epub ahead of print]. | Meta-Analysis | 2014-07 | |
Maitland-van der Zee AH, et al. Patients benefit from genetics-guided coumarin anticoagulant therapy. Clin Pharmacol Ther.2014; 96:15-7. | Commentary | 2014-07 | |
Lachance K et al. Opinions, hopes and concerns regarding pharmacogenomics: a comparison of healthy individuals, heart failure patients and heart transplant recipients. Pharmacogenomics J. 2014; [Epub ahead of print]. | Survey | 2014-07 | |
Patel V et al. Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention. Pharmacy Practice. 2014a;12:438. | Cost-utility analysis | 2014-07 | |
Baker WL et al. New oral anticoagulants vs. warfarin treatment: no need for pharmacogenomics? Clin Pharmacol Ther. 2014;96:17-9. | Perspective | 2014-07 | |
Osnabrugge RL et al. A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel users.Genet Med. 2014 Jun 9; [Epub ahead of print]. | Systematic review | 2014-06 | |
Hokimoto S, et al. Impact of CYP3A5 polymorphism on platelet reactivity at percutaneous coronary intervention and after 9 months of aspirin and clopidogrel therapy in Japanese patients with coronary artery disease. Eur J Clin Pharmacol. 2014;70:667-73. | Prospective cohort study | 2014-06 | |
Cresci S et al. Cytochrome P450 Gene Variants, Race, and Mortality Among Clopidogrel Treated Patients Following Acute Myocardial Infarction. Circ Genetics. 2014;7:277-86. | Prospective cohort study | 2014-06 | Clopidogrel: CYP2C19, CYP1A2 effects in some post-MI patients |
An Sh et al. Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves. J Clin Pharm Ther. 2014; [Epub ahead of print]. | Cross-sectional | 2014-06 | |
Vear SI et al. The impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric population. Br J Haematol. 2014 [Epub ahead of print]. | Cross-sectional | 2014-06 | |
Koller EA, et al. Genotype-guided dosing of vitamin K antagonists. N Engl J Med. 2014;370:1761-66. | Correspondence | 2014-05 | |
Guo B et al. Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease. J Vasc Surg. 2014; [Epub ahead of print]. | Retrospective cohort study | 2014-05 | |
Daly PL et al. Pharmacogenetics of antiplatelet therapy. Curr Atheroscler Rep. 2014;16:411. | Review | 2014-05 | |
Talameh JA et al. Pharmacogenetics of Statin-Induced Myopathy: A Focused Review of the Clinical Translation of Pharmacokinetic Genetic Variants. J Pharmacogenomics Pharmacoproteomics. 2014;5:128. | Review | 2014-04 | |
Scott SA et al. Warfarin pharmacogenetic trials: is there a future for pharmacogenetic-guided dosing? Pharmacogenomics. 2014;15:719-22. | Editorial | 2014-04 | |
Kazi DS et al. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. Ann Intern Med. 2014;160:22132. | Cost-Effective Analysis | 2014-02 | |